Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.85.

EBIT: As of FY2026 Q1, the actual value is USD -2.749 M.

Operational Metrics

Research and Development (R&D) ExpensesFor the three months ended March 31, 2026, R&D expenses were $1,370 thousand, an increase of 133.3% from $590 thousand for the same period in 2025. This increase was primarily due to approximately $700 thousand in higher subcontractor and consultant expenses related to toxicology studies, product development, and GMP manufacturing, as well as approximately $100 thousand in non-cash share-based compensation expenses .

General and Administrative (G&A) ExpensesG&A expenses for the three months ended March 31, 2026, were $1,379 thousand, up 27.3% from $1,060 thousand in the prior-year period. This rise was mainly driven by approximately $260 thousand in higher professional services costs and approximately $200 thousand in non-cash share-based compensation expenses .

Total Operating ExpensesTotal operating expenses for the three months ended March 31, 2026, were $2,749 thousand, compared to $1,650 thousand for the same period in 2025 .

Operating LossThe operating loss was - $2,749 thousand for the three months ended March 31, 2026, compared to an operating loss of - $1,650 thousand for the same period in 2025 .

Financial Expense (Income), NetNet financial income was - $16 thousand for the three months ended March 31, 2026, compared to a financial expense of $85 thousand for the same period in 2025 .

Net LossSilexion Therapeutics Corp reported a net loss of - $2,733 thousand for the three months ended March 31, 2026, an increase of 58.8% from the net loss of - $1,735 thousand for the same period in 2025. This increase was primarily attributed to higher research and development expenses and general and administrative expenses .

Loss Per Share, Basic and DilutedLoss per share, basic and diluted, was - $0.85 for the three months ended March 31, 2026, compared to - $3.84 for the same period in 2025 .

Cash and Balance Sheet Metrics

Cash and Cash EquivalentsCash and cash equivalents decreased to $2,413 thousand as of March 31, 2026, from $5,991 thousand as of December 31, 2025. This decrease primarily reflects ongoing operating expenses supporting preclinical and clinical readiness activities .

Total AssetsTotal assets were $4,602 thousand as of March 31, 2026, down from $7,215 thousand as of December 31, 2025 .

Total LiabilitiesTotal liabilities were $4,311 thousand as of March 31, 2026, compared to $4,612 thousand as of December 31, 2025 .

Total Shareholders’ Equity (Capital Deficiency)Total shareholders’ equity was $291 thousand as of March 31, 2026, a decrease from $2,603 thousand as of December 31, 2025 .

Unique Metrics

Subsequent Capital Raising and Nasdaq ComplianceSubsequent to the quarter end, Silexion Therapeutics Corp generated approximately $1.0 million in gross proceeds from a May 2026 warrant exercise inducement transaction and through its at-the-market facility . The company anticipates these transactions, along with additional equity-increasing activities, have raised its shareholders’ equity above the $2.5 million minimum required for continued listing on the Nasdaq Capital Market, thereby restoring compliance .

Outlook / Guidance

Silexion Therapeutics Corp expects to initiate its Phase ²⁄₃ clinical trial for SIL204 in locally advanced pancreatic cancer in the second quarter of 2026. This trial will begin with an initial safety run-in cohort of approximately 18 patients, followed by an expansion into a randomized cohort of about 166 patients. The company is actively exploring financing options to support the clinical advancement of SIL204 .